 |
2 Products |  |
14 Diseases | | 2 Products |
|
4 Trials |  |
199 News |  |
| «12 |
- ketamine / Generic mfg., L-4-chlorokynurenine (AV-101) / VistaGen
The Impact of Ketamine and AV-101 on the Kynurenine Pathway in Subjects With Treatment-Resistant Unipolar or Bipolar Depression () - Apr 17, 2020 - Abstract #SOBP2020SOBP_1137;
P2
Unlike ketamine, AV-101 had no significant treatment efficacy in subjects with treatment-resistant MDD and no significant effects on the KYN pathway or related peripheral and central measures. Funding Source: National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIA MH002857; NCT02484456)
- L-4-chlorokynurenine (AV-101) / VistaGen
Cortical Gamma as a Marker of Kynurenine Pathway Engagement in Healthy Veterans Receiving L-4-Chloro-Kynurenine (AV-101) (Americas Hall I & II) - Apr 17, 2020 - Abstract #SOBP2020SOBP_990;
More broadly, combining EEG and KP metabolites could be used to inform multimodal biomarkers of NMDAR target engagement. Future studies could examine the effect of AV-101 dose on suicide risk, which has been associated with KP dysregulation and increased activation of NMDARs.
- | aloradine nasal spray (PH94B NS) / VistaGen, Pherin Pharmaceuticals, Inc.
Journal, Interview: An Interview with Shawn Singh: Chief Executive Officer and Director of VistaGen Therapeutics. (Pubmed Central) - Mar 7, 2020
Future studies could examine the effect of AV-101 dose on suicide risk, which has been associated with KP dysregulation and increased activation of NMDARs. No abstract available
- | L-4-chlorokynurenine (AV-101) / VistaGen
Trial completion date, Trial initiation date, Trial primary completion date: AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia (clinicaltrials.gov) - Jan 13, 2020
P2, N=20, Not yet recruiting, Sponsor: VistaGen Therapeutics, Inc.
No abstract available Trial completion date: Jul 2021 --> Apr 2022 | Initiation date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2021
- | L-4-chlorokynurenine (AV-101) / VistaGen
Trial primary completion date: Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder (clinicaltrials.gov) - Dec 6, 2019
P2, N=22, Completed, Sponsor: National Institute of Mental Health (NIMH)
Trial completion date: Jul 2021 --> Apr 2022 | Initiation date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2021 Trial primary completion date: Dec 2019 --> Feb 2019
- | L-4-chlorokynurenine (AV-101) / VistaGen
Trial completion: Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder (clinicaltrials.gov) - Dec 5, 2019
P2, N=22, Completed, Sponsor: National Institute of Mental Health (NIMH)
Trial primary completion date: Dec 2019 --> Feb 2019 Recruiting --> Completed
- || L-4-chlorokynurenine (AV-101) / VistaGen
Biomarker, Trial completion: Electrophysiological Biomarkers of AV-101 (clinicaltrials.gov) - Nov 15, 2019
P1/2, N=12, Completed, Sponsor: Marijn Lijffijt, PhD
Recruiting --> Completed Recruiting --> Completed
- ||| L-4-chlorokynurenine (AV-101) / VistaGen
P2 data: $VTGN Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder. #Fail (Twitter) - Nov 14, 2019
- || L-4-chlorokynurenine (AV-101) / VistaGen
New P2 trial: AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia (clinicaltrials.gov) - Nov 3, 2019
P2, N=20, Not yet recruiting, Sponsor: VistaGen Therapeutics, Inc.
- L-4-chlorokynurenine (AV-101) / VistaGen
Evoked and Resting State Gamma Mechanics to Test NMDA Receptor Engagement of Kynurenine Pathway Modulator AV-101 in Healthy Veterans (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_1240;
High dose AV-101 is associated with increased gamma ITPC, indicating stronger event-related interneuron firing. These findings are consistent with NMDAR blockade by AV-101.
- L-4-chlorokynurenine (AV-101) / VistaGen
A Randomized Trial of the NMDAR Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression (Floridian Ballroom) - Oct 17, 2019 - Abstract #ACNP2019ACNP_730;
In this small cross-over trial, 4-Cl-KYN monotherapy had no antidepressant effect or anti-anxiety efficacy in this sample of subjects with treatment-resistant MDD subjects. Furthermore, 4-Cl-KYN appeared to have no biochemical effects, as no significant changes were observed in glutamate brain levels measured by 7T 1H-MRS, rs-fMRI connectivity, or peripheral and central measures (including tryptophan/kynurenine metabolites).
- | L-4-chlorokynurenine (AV-101) / VistaGen
Trial completion, Trial completion date: ELEVATE: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression (clinicaltrials.gov) - Oct 9, 2019
P2, N=180, Completed, Sponsor: VistaGen Therapeutics, Inc.
Furthermore, 4-Cl-KYN appeared to have no biochemical effects, as no significant changes were observed in glutamate brain levels measured by 7T 1H-MRS, rs-fMRI connectivity, or peripheral and central measures (including tryptophan/kynurenine metabolites). Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Oct 2019
- | L-4-chlorokynurenine (AV-101) / VistaGen
Enrollment closed, Trial completion date, Trial primary completion date: ELEVATE: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression (clinicaltrials.gov) - Aug 15, 2019
P2, N=180, Active, not recruiting, Sponsor: VistaGen Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Oct 2019 Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Nov 2019
- || L-4-chlorokynurenine (AV-101) / VistaGen
Clinical: $VTGN Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for MDD. Topline Data Before EOY'19. (Twitter) - Aug 15, 2019
- | ganaxolone oral (CCD-1042) / Marinus
Review, Journal: A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. (Pubmed Central) - Aug 3, 2019
Here, we review progress in the development of compounds that act on these systems as well as their purported mechanisms of action. We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC-301/MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (RO4917523), decoglurant (RG-1578/RO4995819), tulrampator (CX-1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217.
- | L-4-chlorokynurenine (AV-101) / VistaGen
Biomarker, Trial completion date, Trial primary completion date: Electrophysiological Biomarkers of AV-101 (clinicaltrials.gov) - Jul 9, 2019
P1/2, N=12, Recruiting, Sponsor: Marijn Lijffijt, PhD
We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC-301/MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (RO4917523), decoglurant (RG-1578/RO4995819), tulrampator (CX-1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217. Trial completion date: Mar 2019 --> Oct 2019 | Trial primary completion date: Mar 2019 --> Oct 2019
- | Journal: Glutamatergic Modulators in Depression. (Pubmed Central) - Jun 7, 2019
These results have prompted the repurposing or development of other glutamatergic modulators, both as monotherapy or adjunctive to other therapies. Here, we highlight the evidence supporting the antidepressant effects of various glutamatergic modulators, including (1) broad glutamatergic modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine [Nuedexta], AVP-786, nitrous oxide [N2O], AZD6765), (2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (CP-101,606/traxoprodil, MK-0657 [CERC-301]), (3) glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and (4) metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant, JNJ40411813/ADX71149, R04995819 [RG1578]).
- | L-4-chlorokynurenine (AV-101) / VistaGen
Biomarker, Enrollment open, Trial completion date, Trial primary completion date: Electrophysiological Biomarkers of AV-101 (clinicaltrials.gov) - Oct 30, 2018
P1/2, N=12, Recruiting, Sponsor: Marijn Lijffijt, PhD
Here, we highlight the evidence supporting the antidepressant effects of various glutamatergic modulators, including (1) broad glutamatergic modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine [Nuedexta], AVP-786, nitrous oxide [N2O], AZD6765), (2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (CP-101,606/traxoprodil, MK-0657 [CERC-301]), (3) glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and (4) metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant, JNJ40411813/ADX71149, R04995819 [RG1578]). Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019
- | L-4-chlorokynurenine (AV-101) / VistaGen
Biomarker, New P1/2 trial: Electrophysiological Biomarkers of AV-101 (clinicaltrials.gov) - Jul 15, 2018
P1/2, N=12, Not yet recruiting, Sponsor: Marijn Lijffijt, PhD
- |||| L-4-chlorokynurenine (AV-101) / VistaGen
Enrollment open, Trial completion date, Trial primary completion date: ELEVATE: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression (clinicaltrials.gov) - Mar 9, 2018
P2, N=180, Recruiting, Sponsor: VistaGen Therapeutics, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Mar 2019 | Trial primary completion date: Sep 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Jan 2019 --> Apr 2019
- ||| L-4-chlorokynurenine (AV-101) / VistaGen
Trial initiation date: ELEVATE: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression (clinicaltrials.gov) - Aug 3, 2017
P2, N=180, Not yet recruiting, Sponsor: VistaGen Therapeutics, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Jan 2019 --> Apr 2019 Initiation date: Jun 2017 --> Jan 2018
- ||||| L-4-chlorokynurenine (AV-101) / VistaGen
New P2 trial: ELEVATE: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression (clinicaltrials.gov) - Mar 12, 2017
P2, N=180, Not yet recruiting, Sponsor: VistaGen Therapeutics, Inc.
- L-4-chlorokynurenine (AV-101) / VistaGen
New P2 trial: Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder (clinicaltrials.gov) - Jun 29, 2015
P2, N=25, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
- | L-4-chlorokynurenine (AV-101) / VistaGen
Trial completion: Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers (clinicaltrials.gov) - Oct 22, 2012
P1, N=50, Completed, Sponsor: VistaGen Therapeutics, Inc.
Initiation date: Jun 2017 --> Jan 2018 Not yet recruiting --> Completed
- | L-4-chlorokynurenine (AV-101) / VistaGen
New P1 trial: Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers (clinicaltrials.gov) - Nov 29, 2011
P1, N=50, Completed, Sponsor: VistaGen Therapeutics, Inc.